RxDoctor Payments Data

Jacqueline Skarre

Adult Health · Stony Brook, NYNPI 1578869897

Payments from drug & device makers

$4,868in general payments, 2019–2025

Across 39 payments — averaging $124.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$3K
  • Actelion Pharmaceuticals US, Inc.$689
  • Bayer$400
  • Merck$157
  • Boehringer Ingelheim$144
  • Sandoz$24
$1,786in research payments, 2019–2025

Across 13 payments — averaging $137.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$2K

What the payments were for

  • Consulting fees$90632%
  • Food & beverage$1,21943%
  • Education$72325%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,868 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$28,963
Medicare patients
139
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil79$1,755,763
UptraviSelexipag70$1,635,120
OfevNintedanib Esylate104$1,296,019
OpsumitMacitentan88$1,082,845
Ambrisentan39$256,880
AdempasRiociguat18$252,095
Tadalafil70$173,713
Orenitram ErTreprostinil Diolamine18$142,206
EsbrietPirfenidone14$132,624
Sildenafil Citrate43$39,000
Pirfenidone24$35,801
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$18,611
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,678
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,484
Spiriva RespimatTiotropium Bromide14$9,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$689$2,717,965158 claims
Boehringer IngelheimOfev, Spiriva Respimat$144$1,305,902118 claims
BayerAdempas$400$252,09518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.

Other adult health in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →